Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Dimerix Limited ( (AU:DXB) ).
Dimerix Limited announced a US licensing transaction for their Phase 3 clinical asset, DMX-200, aimed at treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The company is hosting an investor webinar to discuss this development and the progress of their clinical trials. This move is significant for Dimerix as it could enhance their market positioning by addressing an unmet medical need and potentially securing market exclusivity through Orphan Drug Designation incentives in the US and Europe.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, particularly kidney diseases. Their primary product candidate, DMX-200, is in Phase 3 clinical trials for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder. Dimerix also develops DMX-700 for respiratory diseases, utilizing their proprietary Receptor-HIT technology to identify new drug opportunities.
YTD Price Performance: 41.18%
Average Trading Volume: 1,602,835
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$268.5M
Learn more about DXB stock on TipRanks’ Stock Analysis page.